RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zai Lab acquired greater China rights to Novocure ‘s Optune, paying $15 million upfront. Optune is a therapy that uses electric fields, called Tumor Treating Fields, that are tuned to specific frequencies to treat cancer. The fields disrupt cell division, inhibiting tumor growth. The treatment is approved to treat brain cancer. In addition to the upfront payment, Zai will also make development, regulatory and commercial milestone payments, plus royalties. Zai will help Novocure by accelerating patient enrollment for new indications.
Source: China Biotoday
